PD07-05: Local Recurrence Risk in 6377 Patients with Early Breast Cancer Receiving Neoadjuvant Anthracycline-Taxane +/− Trastuzumab Containing Chemotherapy.

Author(s):  
G von Minckwitz ◽  
M Kaufmann ◽  
S Kümmel ◽  
PA Fasching ◽  
W Eiermann ◽  
...  
2005 ◽  
Vol 41 (17) ◽  
pp. 2637-2644 ◽  
Author(s):  
A.C. Voogd ◽  
F.J. van Oost ◽  
E.J.T. Rutgers ◽  
P.H.M. Elkhuizen ◽  
A.N. van Geel ◽  
...  

1995 ◽  
Vol 13 (12) ◽  
pp. 2869-2878 ◽  
Author(s):  
R Arriagada ◽  
L E Rutqvist ◽  
A Mattsson ◽  
A Kramar ◽  
S Rotstein

PURPOSE To analyze different events that determine event-free survival (EFS) in a randomized trial on adjuvant radiotherapy in early breast cancer patients with more than 15 years of follow-up evaluation. PATIENTS AND METHODS The trial included 960 patients with a unilateral, operable breast cancer. Surgery consisted of a modified radical mastectomy. The trial compared three arms, as follows: preoperative radiotherapy, postoperative radiotherapy, and no adjuvant treatment. Events were analyzed by a competing-risk approach. A proportional hazards multiple regression model was used to analyze the effects of radiotherapy on the risk of distant metastasis. Similar analyses were performed separately for node-negative [N(-)] and node-positive [N(+)] patients in the two groups that did not include preoperative radiotherapy. RESULTS Radiotherapy produced a fivefold decrease of the risk of local recurrence (P < .0001). In N(+) patients, postoperative radiotherapy decreased the risk of distant dissemination (relative risk, 0.63). When local recurrence was introduced in the model as a time-dependent covariate, this factor was predictive of distant dissemination (P < .0001) and nullified the effect of postoperative radiotherapy. This finding suggests that the decrease of distant metastases was related to the prevention of local recurrence. A similar effect was found in models that used overall survival as an end point. CONCLUSION This study shows that postmastectomy radiotherapy in N(+) breast cancer patients may decrease the distant metastasis rate by preventing local recurrences and thus avoiding secondary dissemination.


The Breast ◽  
2015 ◽  
Vol 24 ◽  
pp. S118-S119
Author(s):  
R. Nagaoka ◽  
J. Horiguchi ◽  
D. Takata ◽  
A. Sato ◽  
H. Tokiniwa ◽  
...  

The Breast ◽  
2013 ◽  
Vol 22 (3) ◽  
pp. 351-356 ◽  
Author(s):  
Maurice J.C. van der Sangen ◽  
Sanne W.M. Scheepers ◽  
Philip M.P. Poortmans ◽  
Ernest J.T. Luiten ◽  
Grard A.P. Nieuwenhuijzen ◽  
...  

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 517-517 ◽  
Author(s):  
Jason Christiansen ◽  
John M. S. Bartlett ◽  
Mark Gustavson ◽  
David Rimm ◽  
Tammy Robson ◽  
...  

517 Background: Hormone receptors, HER2 and Ki67 are residual risk markers in early breast cancer. Combining these markers into a unified algorithm (IHC4) provides information on residual recurrence risk of patients treated with hormone therapies. This study aimed to independently investigate the validity of the IHC4 algorithm for residual risk prediction using both conventional (DAB)-IHC and quantitative immunofluorescence (QIF-AQUA). Methods: The TEAM pathology study recruited >4500 samples from patients treated in the TEAM trial. TMAs were stained for ER, PgR, HER2 and Ki67 using QIF-AQUA technology or DAB-based immunohistochemistry (DAB-IHC). Central HER2 FISH was performed. Quantitative image analysis was used to generate expression scores that were normalized to produce “IHC4 algorithm” as well as novel algorithm scores.  Algorithm scores were compared with disease recurrence in univariate and multivariate Cox Proportional Hazards models. Results: Both DAB-IHC and QIF-AQUA IHC4 continuous models were significant (P<0.0001) for prediction of disease recurrence with a continuous Hazard Ratio (HR) of 1.011 (1.010 – 1.013) for QIF-AQUA IHC4 versus 1.008 (1.007 – 1.010) for the DAB-IHC IHC4 model using the published IHC4 algorithm (Cuzick et al 2011).  Binning continuous model scores (4 bins) by Kaplan-Meier survival analysis was used to graphically illustrate these effects.  De novo models for both DAB-IHC and QIF-AQUA were also significantly (P<0.0001) predictive of residual risk in early breast cancer. Additionally, all 4 models were independent predictors of recurrence (P<0.0001) with other recognized clinical prognostic factors in multivariate analysis.  Although results from DAB and QIF-AQUA were modestly correlated, the QIF-AQUA model showed enhanced prediction of recurrence in both Cox Proportional Hazards Modeling and C-index calculations. Conclusions: Either conventional DAB or QIF-AQUA methods of IHC provided evidence supporting the clinical utility of IHC4 algorithms in the context of the TEAM study.  With careful standardization, either of these IHC4 assays should be considered for prediction of residual risk in early breast cancer.


Sign in / Sign up

Export Citation Format

Share Document